Latest Pharmaceutical Companies News

EVE Health Group has increased its placement funding to $1.3 million, backed by a cornerstone investor with pharmaceutical expertise, advancing its reformulated drug programs targeting billion-dollar global markets.

dorsaVi has secured significant commercial and clinical milestones with new elite sports and European clinical partnerships, showcasing its advanced real-time AI sensor technology.

Resonance Health has received a $732,851 refund from the Australian Taxation Office, reflecting its FY2025 R&D tax incentive claim net of income tax payable. This cash inflow strengthens the company’s financial position ahead of its March quarterly report.

EVE Health Group has raised $0.9 million to advance its pharmaceutical reformulation programs targeting global markets worth over US$30 billion. The funding will support development of improved delivery technologies for medicines nearing patent expiry.

EVE Health Group has completed R&D on multiple reformulated drug candidates targeting major sexual health and cardiovascular markets, preparing patent filings and licensing strategies to capitalise on a combined $30 billion global opportunity.

Bioxyne Limited has reported a remarkable half-year performance, with revenues soaring 149% to $31.3 million and net profit more than doubling to $7.3 million, driven by strong demand for medicinal cannabis, MDMA, and psilocybin products and expanding international operations.

Mayne Pharma has initiated legal proceedings against Cosette Pharmaceuticals and associated parties, seeking substantial damages following the collapse of their acquisition deal.

Clever Culture Systems posted a $1.32 million loss for the half year ending December 2025, reflecting a strategic shift and reduced government grants. Despite this, the company strengthened its cash position, repaid government debt, and grew its APAS Independence instrument footprint globally.

Hydralyte USA has implemented targeted headcount reductions saving around US$25,000 monthly and completed manufacturing runs to resolve supply shortages, replenishing inventory with key distributors to support near-term sales growth.

Algorae Pharmaceuticals has secured a key Licence & Supply Agreement with Cadila Pharmaceuticals to commercialise two generic cardiovascular and metabolic medicines in Australia and New Zealand, broadening its therapeutic reach beyond oncology.

The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.

Vectus Biosystems is close to finalising a $4.3 million transaction with Canadian biotech XORTX Therapeutics, while actively pursuing licensing opportunities for its anti-fibrotic drug candidates amid cost reductions.